Investing.com -- Immuneering Corp (NASDAQ:IMRX) stock surged 21.7% Monday after the clinical-stage oncology company announced ...

Immuneering (IMRX) partners with Eli Lilly to test atebimetinib + olomorasib in a phase 2 trial targeting KRAS G12c-mutant ...

Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ...

The ELI-002 2P vaccine is an "off-the-shelf" therapy targeting KRAS mutations common in pancreatic and colorectal cancers.

RAS is the most mutated oncogene in cancer (about 30% rate), where mutations in KRAS are the most prevalent. The approval of covalent KRAS G12C inhibitors has shown allosteric inhibition of KRAS to be ...

While phase 1 data suggest the novel vaccine can boost immunity and reduce relapse in pancreatic and colorectal cancer, experts remain cautious at this initial stage.

Colorectal cancer (CRC) is a type of cancer that originates in the colon or rectum from precancerous polyps, which can evolve ...

Colorectal cancer (CRC) is a significant global health concern, originating from precancerous polyps in the colon or rectum and progressing through ...

Researchers found that the vaccine, named ELI-002 2P, could trigger lasting immune responses and may help prevent or delay ...

Technology company Tempus AI has announced the acquisition of Paige, a company focused on digital pathology and AI, for a ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...